Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Stock analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.28) per share for the year, up from their previous forecast of ($0.30). HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Oncolytics Biotech's Q1 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.28) EPS, FY2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.09) EPS and FY2028 earnings at $0.41 EPS.
Several other research firms also recently weighed in on ONCY. Leede Financial downgraded Oncolytics Biotech from a "strong-buy" rating to a "moderate buy" rating in a report on Wednesday, November 13th. Raymond James upgraded shares of Oncolytics Biotech to a "moderate buy" rating in a report on Thursday, November 14th.
Check Out Our Latest Report on Oncolytics Biotech
Oncolytics Biotech Price Performance
Shares of ONCY stock traded up $0.05 during mid-day trading on Wednesday, hitting $0.79. The stock had a trading volume of 2,165,959 shares, compared to its average volume of 2,302,154. Oncolytics Biotech has a 12-month low of $0.67 and a 12-month high of $1.53. The firm's 50-day moving average is $0.85 and its two-hundred day moving average is $0.97. The firm has a market capitalization of $63.61 million, a P/E ratio of -2.94 and a beta of 1.24.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Oncolytics Biotech stock. Vantage Point Financial LLC purchased a new position in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 29,744 shares of the company's stock, valued at approximately $27,000. Institutional investors own 6.82% of the company's stock.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Recommended Stories
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
